Home/Filings/4/0001415889-25-006919
4//SEC Filing

Dierks Jeffrey 4

Accession 0001415889-25-006919

CIK 0001802665other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:05 PM ET

Size

11.1 KB

Accession

0001415889-25-006919

Insider Transaction Report

Form 4
Period: 2025-03-03
Dierks Jeffrey
CHIEF COMMERCIAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-03$8.22/sh+4,869$40,0234,869 total
  • Sale

    Common Stock

    2025-03-03$32.61/sh4,369$142,474500 total
  • Sale

    Common Stock

    2025-03-03$33.23/sh500$16,6150 total
  • Exercise/Conversion

    Stock Option

    2025-03-034,8690 total
    Exercise: $8.22Exp: 2030-03-04Common Stock (4,869 underlying)
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The stock option vests in five equal annual installments beginning on March 1, 2021.

Issuer

Harmony Biosciences Holdings, Inc.

CIK 0001802665

Entity typeother

Related Parties

1
  • filerCIK 0001821102

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:05 PM ET
Size
11.1 KB